Oct 9, 2015
BARCELONA — A reanalysis of phase III data on teriflunomide (Aubagio) shows that both doses of the drug result in significant reduction of brain volume loss vs. placebo in patients with relapsing multiple sclerosis (RMS).
Ludwig Kappos, MD, of the University Hospital of Basel in Basel, Switzerland, and fellow researchers presented the data at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in Barcelona.
For this study, Professor Kappos and colleagues analyzed changes in brain volume from MRI data from the TEMSO study using the SIENA methodology in patients treated with Aubagio 14 mg or 7 mg or placebo. Previously, Aubagio 14 mg was found to significantly reduce the risk of disability progression in patients with RMS.